(Reuters) - AstraZeneca’s (AZN.L) experimental COVID-19 vaccine was safe and produced an immune response in early-stage clinical trials in healthy volunteers, data showed on Monday.
Drugmakers are racing to combat the pandemic that has now killed nearly 600,000 people.
There are no approved vaccines for COVID-19, but the World Health Organization (WHO) has said AstraZeneca’s shot is one of the leading candidates.
Here are the main details about AstraZeneca’s experimental vaccine and its supply and production deals:
Sources: Reuters reporting, press releases
Reporting by Pushkala Aripaka and Tanishaa Nadkar in Bengaluru; editing by Jason Neely, Nick Macfie and Sherry Jacob-Phillips